Ellen Feigal
Directeur/Membre du Conseil chez NEXTCURE, INC.
Fortune : - $ au 30/04/2024
Profil
Ellen G.
Feigal is currently the Director at Spectral Medical, Inc., Independent Director at Xencor, Inc., Independent Non-Executive Director at Prescient Therapeutics Ltd., Independent Director at NextCure, Inc., and Partner at NDA Partners LLC.
Previously, she held positions such as Executive Medical Director-Global Development at Amgen, Inc., Director at The University of California, San Francisco, Deputy Director-Cancer Treatment Division at the National Cancer Institute, Director-Medical Devices & Imaging at Critical Path Institute, Director-American Course on Drug Development at the University of California, Vice President-Research & Development at the California Institute for Regenerative Medicine, Vice President-Clinical Sciences at Translational Genomics Research Institute, and Chief Medical Officer at INSYS Therapeutics, Inc. Dr. Feigal has a graduate degree from the University of California, Berkeley, a doctorate degree from the University of California, Davis, an undergraduate degree from the University of Minnesota, and a doctorate degree from Stanford University School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NEXTCURE, INC.
-.--% | 22/06/2023 | 0 ( -.--% ) | - $ | 30/04/2024 |
XENCOR, INC.
-.--% | 29/02/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Ellen Feigal
| Sociétés | Poste | Début |
|---|---|---|
| NEXTCURE, INC. | Directeur/Membre du Conseil | 01/10/2021 |
| PRESCIENT THERAPEUTICS LIMITED | Directeur/Membre du Conseil | 15/05/2023 |
NDA Partners LLC
 NDA Partners LLC Miscellaneous Commercial ServicesCommercial Services NDA Partners LLC provides strategy consulting services. It also provides a comprehensive range of services across the product development life cycle for drugs, biologics, biosimilars, vaccines, generics, devices, combination products and diagnostics. The company was founded by Carl C. Peck and Earle Martin and is headquartered in Annapolis, MD. | Corporate Officer/Principal | 01/12/2014 |
Anciens postes connus de Ellen Feigal
| Sociétés | Poste | Fin |
|---|---|---|
| California Institute for Regenerative Medicine | Directeur Technique/Scientifique/R&D | 01/01/2014 |
| AMGEN INC. | Corporate Officer/Principal | 01/01/2011 |
| INSYS THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2008 |
Critical Path Institute
 Critical Path Institute Miscellaneous Commercial ServicesCommercial Services Critical Path Institute is a nonprofit organization established in 2005 as a public and private partnership with the FDA's Critical Path Initiative program. The non-profit company is based in Tucson, AZ, and operates from Ireland with additional staff in multiple other locations. The company's mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. The company orchestrates the development of drug development tools through an innovative, collaborative approach to the sharing of data and expertise, and accelerate the pace and reduce the costs of medical product development by building consensus among the participating institutions. The company was founded in 2005 by Raymond L. Woosley, Glenn C. Rice. Daniel M. Jorgensen has been the CEO of the company since 2022. | Corporate Officer/Principal | 01/01/2007 |
Translational Genomics Research Institute
 Translational Genomics Research Institute Miscellaneous Commercial ServicesCommercial Services Translational Genomics Research Institute operates as non-profit organization. It focuses on developing earlier diagnoses and smarter treatments. Translational research applies to the development of diagnostics, prognostics, and therapies for cancer, neurological disorders, diabetes, and other complex diseases. The company was founded by Jeffrey M. Trent in 2002 and is headquartered in Phoenix, AZ. | Corporate Officer/Principal | 01/01/2007 |
Formation de Ellen Feigal
| University of California, Berkeley | Graduate Degree |
| University of California, Davis | Doctorate Degree |
| University of Minnesota | Undergraduate Degree |
| Stanford University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| PRESCIENT THERAPEUTICS LIMITED | Health Technology |
| NEXTCURE, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Miscellaneous |
| California Institute for Regenerative Medicine | Government |
NDA Partners LLC
NDA Partners LLC Miscellaneous Commercial ServicesCommercial Services NDA Partners LLC provides strategy consulting services. It also provides a comprehensive range of services across the product development life cycle for drugs, biologics, biosimilars, vaccines, generics, devices, combination products and diagnostics. The company was founded by Carl C. Peck and Earle Martin and is headquartered in Annapolis, MD. | Commercial Services |
Translational Genomics Research Institute
Translational Genomics Research Institute Miscellaneous Commercial ServicesCommercial Services Translational Genomics Research Institute operates as non-profit organization. It focuses on developing earlier diagnoses and smarter treatments. Translational research applies to the development of diagnostics, prognostics, and therapies for cancer, neurological disorders, diabetes, and other complex diseases. The company was founded by Jeffrey M. Trent in 2002 and is headquartered in Phoenix, AZ. | Commercial Services |
Critical Path Institute
Critical Path Institute Miscellaneous Commercial ServicesCommercial Services Critical Path Institute is a nonprofit organization established in 2005 as a public and private partnership with the FDA's Critical Path Initiative program. The non-profit company is based in Tucson, AZ, and operates from Ireland with additional staff in multiple other locations. The company's mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. The company orchestrates the development of drug development tools through an innovative, collaborative approach to the sharing of data and expertise, and accelerate the pace and reduce the costs of medical product development by building consensus among the participating institutions. The company was founded in 2005 by Raymond L. Woosley, Glenn C. Rice. Daniel M. Jorgensen has been the CEO of the company since 2022. | Commercial Services |
INSYS Therapeutics, Inc.
 INSYS Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology INSYS Therapeutics, Inc. operates as a pharmaceutical company, which develops and commercializes supportive care products. It focuses on utilizing commercial pharmaceutical products that include Subsys, a proprietary sublingual fentanyl spray for BTCP in opioid-tolerant adult patients; and Syndros, a proprietary orally administered liquid formulation of dronabinol for the treatment of CINV and anorexia associated with weight loss in patients with AIDS. The company was founded by John N. Kapoor on June 15, 1990 and is headquartered in Chandler, AZ. | Health Technology |
